Adults: Zofran tablets are indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. Zofran tablets are indicated for the prevention of post-operative nausea and vomiting (PONV). For treatment of established PONV, administration by injection is recommended. Paediatric Population: Zofran is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in children aged ≥6 months. No studies have been conducted on the use of orally administered ondansetron in the prevention and treatment of PONV in children aged ≥1 month, administration by IV injection is recommended for this purpose.
Adults: Zofran Melt is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. Zofran Melt is indicated for the prevention of post-operative nausea and vomiting (PONV). For treatment of established PONV, administration by injection is recommended. Paediatric Population: Zofran is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in children aged ≥6 months No studies have been conducted on the use of orally administered ondansetron in the prevention and treatment of PONV in children aged ≥1 month, administration by IV injection is recommended for this purpose.
Adults: Zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. Zofran is indicated for the prevention and treatment of post-operative nausea and vomiting (PONV). Paediatric Population: Zofran is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in children aged ≥6 months, and for the prevention and treatment of PONV in children aged ≥1 month.
Adults: Ondansetron is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. Ondansetron is indicated for the prevention and treatment of post-operative nausea and vomiting (PONV). Paediatric Population: Ondansetron is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in children aged ≥6 months, and for the prevention and treatment of PONV in children aged ≥1 month.